Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Strategic design and targeted use of pharmacodynamic measures can greatly assist in evaluating the safety and potential efficacy of your new drug candidate in the early stages of clinical development.
In this on-demand webinar, our experts discuss how to include validated models of pain, anxiety, and other psychiatric conditions as part of a battery of tests for cognition and safety, to evaluate a drug’s potential for abuse or dependence, as well as its ability to enhance or impair performance.
You may also be interested in the following:
- The Altascientist: Considerations for Your CNS-active Drug Development Program
- Webinar — Assessing Cognition and Driving Ability in Clinical Pharmacology Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.